Meropenem Dosage Strategy Based on PPK Model

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qingtao Zhou
• Treatments: Meropenem; Thienamycins

Criteria

Inclusion Criteria:

• Sixty years and older patients hospitalized at the Peking University Third Hospital with community-acquired or hospital-acquired lower respiratory tract infection.

• Bacilli was idolated from lower respiratory tract specimens within 48 hours prior to study enrollment.

• The pathogen was sensitive to meropenem.

• Received broad-spectrum antibiotic therapy less than 24 hours, or no improvement after antibiotic therapy and pathogen was resistant to the used antibiotics.

Exclusion Criteria:

• Had documented hypersensitivity to carbapenems.

• More than one pathogenic Gram-negative bacillus was isolated lower respiratory tract specimens.

• Positive HIV antibody titre.

• Had known or suspected tuberculosis or other infections caused by Gram-positive cocci, viruses or fungi at baseline.